Literature DB >> 3298618

Models for the pharmacokinetics and pharmacodynamics of insulin in alloxan-induced diabetic dogs.

S A Brown, R W Nelson, G D Bottoms.   

Abstract

A combined pharmacokinetic/pharmacodynamic model was proposed to describe the pharmacokinetics of intravenously administered regular insulin (0.55 units/kg) in alloxan-induced diabetic dogs. Serum insulin concentrations were described by either a one- or two-compartment open model, in which a hypothetical effect compartment was linked to the central pharmacokinetic compartment, or in which the effect compartment was linked to the peripheral compartment. Response, as measured by percent change in glucose concentration from adjusted basal plasma concentrations, was modeled using the sigmoidal Emax effect model, a linear effects model, a log-linear effects model, and a gamma-linear effects model, using the insulin pharmacokinetic parameters to describe the amount in the hypothetical effect compartment. The results indicated that insulin pharmacokinetics are usually described by a two-compartment open model. Response to insulin was predicted more accurately in half of the dogs using the gamma-linear effects model in which the effect compartment was linked to the central compartment. In the other half of the dogs the best model was the sigmoidal Emax model in which the effect compartment was linked to the central pharmacokinetic compartment. The parameters in the latter model were correlated with each other and the confidence limits of the parameter estimates were larger than the parameters of the gamma-linear effects model. These models should be further investigated, but may offer an alternative method for distinguishing rapid insulin metabolism from insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3298618     DOI: 10.1002/jps.2600760406

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

Review 1.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats.

Authors:  Mathangi Gopalakrishnan; Sandra Suarez; Anthony J Hickey; Jogarao V S Gobburu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 3.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.